Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.

This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compounds. ZD1839 has suitable properties for use as a clinically effective drug and shows activity against human tumours. In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.

N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides: KATP potassium channel openers. Modifications on the western region.

A subset of antiandrogen compounds, the N-aryl-3,3,3-trifluoro-2-hydroxy-2-methylpropanamides 1, were found to activate ATP sensitive potassium channels (KATP) and represent a new class of potassium channel openers (PCOs). A structure-activity relationship was carried out on the western region of this series with the goal of obtaining an activator of the ATP sensitive potassium channel suitable for use in the treatment of urge urinary incontinence. In particular three large 4-(N-aryl) substituents, the (N-phenyl-N-methylamino)sulfonyl, benzoyl, and 4-pyridylsulfonyl moieties, yielded non-antiandrogen, KATP potassium channel openers (39, 41, and 64, respectively) that are bladder selective in an in vivo rat model that simultaneously measures bladder contractions, heart rate, and blood pressure. Substitutions of the aryl rings of 41 and 64 gave several derivatives that also display selectivity in the in vivo rat model; however, none appear to offer a substantial advantage over 41 and 64. The PCO activity of 41 and 64 resides in the (S)-(-) enantiomers. ZD6169, 41(S), has been selected into development for the treatment of urge urinary incontinence.

New nonpeptide angiotensin II receptor antagonists. 1. Synthesis, biological properties, and structure-activity relationships of 2-alkyl benzimidazole derivatives.

On the basis of an extension of the literature lead 1, a series of benzimidazoles have been synthesized and shown to be angiotensin II (AII) receptor antagonists. The structure-activity relationships of these new antagonists have been explored and the key binding interactions defined. Molecular mechanics calculations were carried out on analogues of imidazole AII antagonists and conformationally restricted analogues were synthesized. The benzimidazole antagonists displaced AII in binding studies in vitro with IC50 values in the range 10(-5)-10(-7) M and antagonized the hypertensive effects of AII in vivo (rats) following intravenous administration with ED50 values in the range of 5-20 mg/kg.

Identification of novel hydroxy fatty acids in the barnacle Balanus balanoides.

The ability of the barnacle Balanus balanoides tissues to produce eicosanoid hatching factors from endogenous polyunsaturated fatty acids has been investigated. GC-MS analysis of an active HPLC fraction from the trihydroxy fatty acid band on TLC revealed the presence of a number of trihydroxy fatty acids and two compounds which were tentatively identified as chlorinated dihydroxy fatty acids. The identified trihydroxy fatty acids are 10,11,12-trihydroxy-5,8,14-eicosatrienoic acid, 10,11,12-trihydroxy-5,8,14,17-eicosatetraenoic acid, 13,14,15-trihydroxy-5,8,11,17-eicosatetraenoic acid and 12,13,14-trihydroxy-4,7,10,16,19-docosapentaenoic acid. The tentatively identified chlorinated dihydroxy fatty acids are 9-chloro- and/or 11-chloro-8,12-dihydroxyeicosatetraenoic acid. The formation of these compounds is evidence of lipoxygenase activities in Balanus balanoides and their identification will facilitate the understanding of the roles eicosanoids play in barnacle physiology, especially with regard to the larval hatching process.

Radioimmunoassay of LTB4 in plasma from different species: a cautionary note.

In clinical and pre-clinical research the pharmacodynamics of selective 5-lipoxygenase and dual 5-lipoxygenase/cyclo-oxygenase inhibitors may be studied by direct RIA of plasma LTB4. Although immunoreactive LTB4 in plasma from A23187 stimulated human blood has the characteristics of authentic LTB4 our results show, particularly in mice and rats, that exposure to A23187 produces large quantities of 12-HETE. Since in different species the levels of 12-HETE increase with platelet concentration we suggest that the 12(S)-HETE is produced by platelet lipoxygenase. However, we do not rule out the possibility that a proportion of 12-HETE may exist as the (R)-stereoisomer. The latter has greater potential for interference in the direct RIA of LTB4. Biosynthesis of 12-HETE may be measured either by RPHPLC/U.V. abs. (8) or by RIA (9) and LTB4 by a more specific antibody described in this report. We conclude that the combined ex vivo RIA of plasma TXB2, LTB4 and 12-HETE has utility in determining the selectivity of inhibitors of arachidonate metabolism and in distinguishing between selective 5-lipoxygenase inhibitors which interact directly with the enzyme and anti-oxidant or free radical scavenging types which may be less specific.

Identification of the hatching factor of the barnacle Balanus balanoides as the novel eicosanoid 10,11,12-trihydroxy-5,8,14,17-eicosatetraenoic acid.

Barnacle egg hatching factor which is released into the mantle cavity where the egg masses are brooded and stimulates embryonic musculature resulting in hatching and liberation of the larvae into the sea has been isolated in a purified form from a common barnacle Balanus balanoides. Derivatised hatching factor has been analysed by GC-MS and identified as 10,11,12-trihydroxy-5,8,14,12-eicosatetraenoic acid, a novel eicosanoid probably formed from endogenous eicosapentaenoic acid (20:5w3). Hatching factor activity is the first specific physiological function to be established for this type of compound.